Skip to main content
. Author manuscript; available in PMC: 2013 May 1.
Published in final edited form as: J Immunother. 2012 May;35(4):309–320. doi: 10.1097/CJI.0b013e31824b3b14

Figure 1. NE and P3 are elevated in serum from patients with AML and CML.

Figure 1

Serum from HD and patients with AML and CML was analyzed using ELISA. (A) NE level was significantly higher in serum from AML (median= 1058 ng/mL; n = 20) and CML (median= 941.7 ng/mL; n = 15) patients, compared with serum from HD (median= 65.3 ng/mL; n = 5) and AML patients in remission (median= 257.9 ng/mL; n=17). (B) P3 level was also significantly higher in serum from AML patients (median= 902.1 ng/mL; n=22) compared with HD (median= 187.7 ng/mL; n=19) and patients in remission (median= 161.4 ng/mL; n=17).